Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Truxima becomes the first biosimilar MAb in oncology to be granted E.U. marketing authorization

Feb. 23, 2017

Affigen closes series A financing to support development of cancer immunotherapies

Feb. 23, 2017

VBL Therapeutics reports full results from exploratory phase II study of VB-111

Feb. 22, 2017

XBiotech can continue phase III study of Xilonix for treatment of colorectal cancer

Feb. 22, 2017

NewLink Genetics presents phase I data on HyperAcute Renal immunotherapy in patients with RCC

Feb. 22, 2017

Pfizer's BLA for inotuzumab ozogamicin granted priority review by FDA

Feb. 22, 2017

FDA awards fast track designation to CMD-003

Feb. 21, 2017

Immune Pharmaceuticals plans pivotal study of Ceplene in AML to support U.S. approval

Feb. 20, 2017

Chugai seeks Japanese approval for atezolizumab for NSCLC

Feb. 17, 2017

Tracon Pharmaceuticals begins dosing in phase III TAPPAS study of TRC-105

Feb. 17, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...